Yumeng Zhang, MD

Yumeng Zhang, MD

Dr. Yumeng Zhang became an assistant member of the Malignant Hematology Department at the renowned H. Lee Moffitt Cancer Center and Research Institute in 2023. Prior to this, she had completed her hematology and medical oncology fellowship training at the same institution, where she excelled as a chief fellow. An unwavering passion for cancer immunology and the research of rare cancers drives Dr. Zhang's journey into oncology.

Her innovative work in clinical trial design and translational oncology has earned her accolades such as the ASCO Young Investigator Award, the Robert A. Winn Diversity in Clinical Trials Award, and grants including the NIH K05 and the Microbiome Pilot Grant. She also participated in prestigious workshops like the ASCO/AACR Vail Workshop and the SCION Workshop.

Intrigued by the multifaceted nature of T-cell lymphoma, Dr. Zhang has outlined precise and ambitious objectives for her career. Her primary goal is to be recognized as a leading clinical investigator in the realm of T-cell lymphoma therapeutic development. Rather than solely relying on traditional treatment avenues, she emphasizes the integration of immune system modulation with targeted therapies. Such a pioneering approach sets the stage for groundbreaking therapeutic advancements in T-cell lymphoma.

Furthermore, Dr. Zhang is dedicated to refining the treatment and management strategies for rare cancers, such as cutaneous T-cell lymphoma. She aspires to develop or augment a research platform designed explicitly for these rare malignancies. This envisioned platform promises to be pivotal in addressing the current challenges associated with these uncommon diseases' management and therapeutic evolution. Endowed with a drive for cancer immunology and rare cancer research and equipped with the extensive clinical experience gained at the H. Lee Moffitt Cancer Center and Research Institute, Yumeng Zhang is well on the way to making significant contributions to the field of oncology.